All patients received 20 sessions (one hour) of CDT for four weeks (five days per week).Results: There was a statistically significant reduction in the volume of the involved limbs after the treatment (p
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Objectives: To investigate the effects of complex decongestive therapy (CDT) on the quality of life, depression, neuropathic pain, and fatigue in patients with breast cancer-related lymphedema (BCRL).Patients and methods: Between March 2015 and June 2015, a total number of 60 patients (mean age 55.7±10.3 years; range 18 to 85 years) with BCRL were included in the study.
📊
Key Findings & Data:The European Organization for Research and Treatment of Cancer Quality of Life- C30 (EORTC QLQ-C30) for the quality of life, the Brief Fatigue Inventory (BFI) for fatigue, Douleur Neuropathique 4 Questions (DN4) for neuropathic pain, and the Beck Depression Inventory (BDI) for the emotional status were used before and after the treatment.
💡
Conclusion & Impact:All patients received 20 sessions (one hour) of CDT for four weeks (five days per week).Results: There was a statistically significant reduction in the volume of the involved limbs after the treatment (p
🔬Design:Research Article
📍Scope:2015 Verileri
⚙️Variables:Domain Parameters
Abstract
Objectives: To investigate the effects of complex decongestive therapy (CDT) on the quality of life, depression, neuropathic pain, and fatigue in patients with breast cancer-related lymphedema (BCRL).Patients and methods: Between March 2015 and June 2015, a total number of 60 patients (mean age 55.7±10.3 years; range 18 to 85 years) with BCRL were included in the study. Demographic data and previous medical records were recruited from medical files. The European Organization for Research and Treatment of Cancer Quality of Life- C30 (EORTC QLQ-C30) for the quality of life, the Brief Fatigue Inventory (BFI) for fatigue, Douleur Neuropathique 4 Questions (DN4) for neuropathic pain, and the Beck Depression Inventory (BDI) for the emotional status were used before and after the treatment. All patients received 20 sessions (one hour) of CDT for four weeks (five days per week).Results: There was a statistically significant reduction in the volume of the involved limbs after the treatment (p
🔖
Cite This Article
YESİL, H., CARAMAT, İ., IŞIK, R., EYİGÖR, S. (2022). Effects of complex decongestive therapy on quality of life, depression, neuropathic pain, and fatigue in women with breast cancer-related lymphedema. Türkiye Fiziksel Tıp ve Rehabilitasyon Dergisi, Cilt: 63 - Sayı: 4, 329–334. https://ajindex.com/articles/628610
Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012:
Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. Lyon: International Agency for Research on Cancer; 2014. Available from: http://globocan.iarc.fr [Accessed: January 16, 2015] 2. Eyigor S, Kanyilmaz S. Exercise in patients coping with breast cancer: An overview. World J Clin Oncol 2014;5:406-11. 3. Salonen P, Rantanen A, Kellokumpu-Lehtinen PL, Huhtala H, Kaunonen M. The quality of life and social support in significant others of patients with breast cancer--a longitudinal study. Eur J Cancer Care (Engl) 2014;23:274-83. 4. Lasinski BB, McKillip Thrift K, Squire D, Austin MK, Smith KM, Wanchai A, et al. A systematic review of the evidence for complete decongestive therapy in the treatment of lymphedema from 2004 to 2011. PM R 2012;4:580-601. 5. McWayne J, Heiney SP. Psychologic and social sequelae of secondary lymphedema: a review. Cancer 2005;104:457-66. 6. Smoot B, Wong J, Cooper B, Wanek L, Topp K, Byl N, et al. Upper extremity impairments in women with or without lymphedema following breast cancer treatment. J Cancer Surviv 2010;4:167-78. 7. Schmitz KH, Ahmed RL, Troxel AB, Cheville A, LewisGrant L, Smith R, et al. Weight lifting for women at risk for breast cancer-related lymphedema: a randomized trial. JAMA 2010;304:2699-705. 8. Pinto M, Gimigliano F, Tatangelo F, Megna M, Izzo F, Gimigliano R, et al. Upper limb function and quality of life in breast cancer related lymphedema: a cross-sectional study. Eur J Phys Rehabil Med 2013;49:665-73. 9. Shih YC, Xu Y, Cormier JN, Giordano S, Ridner SH, Buchholz TA, et al. Incidence, treatment costs, and complications of lymphedema after breast cancer among women of working age: a 2-year follow-up study. J Clin Oncol 2009;27:2007-14. 10. Mayrovitz HN. The standard of care for lymphedema: current concepts and physiological considerations. Lymphat Res Biol 2009;7:101-8. 11. Forner-Cordero I, Muñoz-Langa J, Forner-Cordero A, DeMiguel-Jimeno JM. Predictive factors of response to decongestive therapy in patients with breast-cancer-related lymphedema. Ann Surg Oncol 2010;17:744-51. 12. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a qualityof-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-76. 13. Mendoza TR, Wang XS, Cleeland CS, Morrissey M, Johnson BA, Wen